Thanks John. Here's a very interesting exercise.
Column 1 is Q4 removing the extra write down of 4771
and changing Cost Of Sales to 30% of 1430 plus the 151,000.
The net effect of this is to clear the one time and set
Pennsaid GP at 70% while keeping Dioptic the same.
Column 2 is the same formula showing Pennsaid sales
necessary to bring Q4 2001 net profit to zero (operational
breakeven).
Column 3 is column 2 divided by 2.15 to reflect pounds
sterling reporting for Q4 2001 with the stated assumptions.
Column 4 is column 3 times 4 to show annualized sales
necessary in pounds sterling to break even based on latest
quarter numbers.
It takes 8.1 million pounds sterling to bring us there out
of a 260 million pound market. We need less than 3% of
our first rinky market (at 70% GP) (just watch). Call it
9% at the Provalis level.
What a laugh. Congratulations Dimethaid. Canada, the EU,
and a decent partner and we'll see you at the AGM.
Rev 1,652,183 4,371,313 2,033,169 8,132,675
Cos 580,055 1,395,794 649,206 2,596,826
G P 1,072,128 2,975,519 1,383,962 5,535,850
Int 75,687 75,687 35,203 140,813
Net 1,147,815 3,051,206 1,419,166 5,676,663
R&D 1,264,017 1,264,017 587,915 2,351,660
Adm 1,349,677 1,349,677 627,757 2,511,027
S&M 333,959 333,959 155,330 621,319
Amz 100,000 100,000 46,512 186,047
Int 3,553 3,553 1,653 6,610
Exp 3,051,206 3,051,206 1,419,166 5,676,663
N P (1,903,391) 0 0 0 |
